Amyris relaunch
Seite 3 von 52 Neuester Beitrag: 15.08.23 16:19 | ||||
Eröffnet am: | 02.07.12 15:53 | von: Bursar | Anzahl Beiträge: | 2.281 |
Neuester Beitrag: | 15.08.23 16:19 | von: Buntspecht5. | Leser gesamt: | 613.324 |
Forum: | Hot-Stocks | Leser heute: | 195 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 | 7 | 8 | 9 | ... 52 > |
Amyris (AMRS) Announces Collaboration with Top 10 Pharmaceutical Company
Article
Related Press Releases (1)
Stock Quotes (1)
Comments (0)
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
StreetInsider.com Top Tickers, 11/26/2016
1. JNJ
2. CTRP
3. ALIOY
4. WMT
5. TGT
6. GILD
7. USO
8. IPCI
9. OIL
10. AMZN
.
Top News
Most Read
Special Reports
Wall Street finishes at record highs consumer staples, techs gain
Actelion Confirms Johnson & Johnson (JNJ) Takeover Approach
'Black Friday' Turning Into 'Couch Friday' - Cowen (WMT) (PINK) (AEO) (TGT) (more...)
Target (TGT) Reports Strong Start to Black Friday in Stores and Record Online Sales
Dollar weakens as U.S. bond yields slip from recent highs
October 28, 2016 2:19 PM EDT
Tweet Share E-mail
Get Alerts AMRS Hot Sheet
Price: $0.81 +2.53%
Overall Analyst Rating:
NEUTRAL (= Flat)
EPS Growth %: +69.6%
Trade AMRS Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, is pleased to announce it has entered into a research agreement with a commercial license option with one of the top 10 largest global pharmaceutical companies. Under the terms of the agreement, the collaboration will use Amyris's µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test its partner’s target antibiotic therapeutic.
Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature's potential is often under-utilized due to scarcity or unavailability. Amyris's µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds.
“We’re pleased to have executed our second large µPharm collaboration during the second half of 2016 as planned,” said John Melo, Amyris President and CEO. “We are continuing to experience significant momentum in our business and within biopharma alone we have now executed agreements with three of the top companies in the industry, each leaders in their fields.”
"Adding another top pharmaceutical company partner to our collaboration portfolio demonstrates the robust growth opportunity we see in the space," said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations. "The flexibility and power of Amyris’s technology platform can be harnessed for a variety of applications and within biopharma can open a new area of compounds that have never been accessible for new drug discovery."
Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against the identified target. This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in in vitro screens to find a drug candidate. Instead, the µPharm platform starts with the target to improve efficiency, identifies candidate natural compound structures, and then creates diversity around those structures for in vivo testing.
Amyris - The Correction Is Over
Apr.12.17 | About: Amyris, Inc. (AMRS)
TechGrows
TechGrows
Long/short equity, growth, tech
Follow
(169 followers)
Summary
•The stock has been driven down by a major shareholder selling stock.
•The selling was not caused by anything Amyris-related and is over now.
•The company will release material updates soon.
•Long term economics are underappreciated by the market.
I have written about Amyris (NASDAQ:AMRS) twice - here and here. The stock went significantly up shortly after both publications. However, while it is up 26% since the publication of the first article, it has corrected form $0.8 per share to $0.5 per share since the publication of the second one.
Why is that? Temasek, a 20%+ shareholder has been selling shares. Since October, they have reduced their holdings from almost 69 million shares to just under 52 million. Temasek is the sovereign investor fund of Singapore. In the fiscal year of 2016 they lost $S24 billion or around 17 billion US dollars. That prompted some management changes and a rebalancing of their US portfolio. That sweeping change in a $200bn fund included reducing their position in Amyris. Selling 17 million shares into the market brought down the stock price and encouraged short sellers (such a large shareholder selling creates a safety cap for them).
However, the selling is over now. Temasek's fiscal year ended on March 31st and they haven't sold a share of AMRS since. I expect the shorts to start covering their record 10 million share position soon.
There are plenty of upside catalysts coming in the near future. Amyris just delayed their 10-K filing because of a material impact of certain "in process" transactions. Since they only get 15 days to file the 10-K, we should expect material news very soon.
In May Amyris is holding an investor day to show their new products, including an artificial sweetener, which is a huge revenue opportunity by itself. Moreover, the company is going to showcase their technology platform, which was partly funded by a DARPA grant, which will enable them to scale production of new molecules in weeks instead of years. That is the single most exciting aspect of Amyris.
Amyris's Biossance Delivers Record First-Quarter Sales — #1 Eye Product at Sephora and On Track for Much Better than Expected 2017
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1021260
ReverseSplit durch. Dann wurde durch Ausgabe neuer Aktien 105 Mio eingesammelt (von strategischen Investoren, die genau wissen, was sie tun). jetzt ca. 45 Mio Aktien draußen. Zahlen von gestern zeigen eine ordentliche Entwicklung. Wenn die das noch einen Augenbllick durchhalten, kann das richtig gut werden. Ein echter Zukunftsmarkt.
- Q2 2017 revenues of $25.7 million, up 168% over $9.6 million for Q2 2016
- Q2 2017 product sales of $12.7 million, up 159% over $4.9 million for Q2 2016
- Completed equity financing and exceeded target with $103 million in total funding from Royal DSM and investors over two tranches and significantly reduced total debt
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1036975
Hier mal zum Vergleich die Intrexon Zahlen, deren Marktkapitalisierung beträgt gut 2 Mrd Dollar!
https://charts.stocktwits.com/production/original_91618642.?1502375497
- die gegebenen ausblicke sind wirklich sensationell (vielleicht täte hier sogar etwas zurückhaltung gut)
- die umsatzsteigerungen in den letzten quartalen können sich ernsthaft sehen lassen (und haben nur enttäuscht, weil man mehr erwartet hat)
- eine refinanzierung ist gelungen und zwar mit ausgesprochen seriösen strategischen investoren
- aktie ist durch eine hohe shortquote sehr in den keller gegangen
- grundstein für eine signifikante ausweitung der produktion in im frühjahr gelegt
- sehr zukunftsträchtiger markt
Wenn nun noch eine weitere Kreditzahlung mit common shares erledigt wird, reduziert sich der Mehrwert der Verwaesserung zu Null. Mit vollem 'Cash Warrant' verkauf haetten wir ungefaehr 64 Millionen Aktien.
Die Firma sollte besser ein Aussage machen, wie es fuer den kleinen Aktionaer weitergeht.
Siehe auch:
- https://investorshub.advfn.com/boards/...sg.aspx?message_id=134086357
- https://seekingalpha.com/instablog/...quity-and-liabilities-reduction
zu den q2 zahlen hat melo doch wieder großspurig verkündet, dass man nun "durchfinanziert sei", im umkehrschluss würde das für mich heißen, kein weiterer finanzbedarf, insbesondere wenn man dann noch seine mehr als optimistischen quartals- und jahresprognosen gegenüberstellt...
problem nur, dass erzählt er schon seit jahren ohne jemals seine selbst gesteckten ziele zu erreichen...ergo vertrauensproblem + dilution...
immerhin, letzten freitag seit wochen die niedrigste shortquote...mal sehen was montag und die nächsten wochen passiert..vielleicht ist das tal der tränen ja vorerst tatsächlich erreicht
By Meghan Tahbaz August 31, 2017
https://www.oreilly.com/ideas/where-beauty-and-biotechnology-intersect
Effekte glaube ... aber dabeisein ist alles .... hier:http://www.meetmax.com/sched/event_39839/~public/...ml?event_id=39839
neues Produkt.
https://www.sephora.com/product/...&icid2=products%20grid:p423678
im süßstoffmarkt ist amyris ja auch unterwegs. hoch interessanter markt:
http://www.coca-colacompany.com/stories/...enges-to-find-next-generat
man könnte ja denken, die aktie sei ordentlich gestiegen ... weil es jetzt ein paar grüne tage gab ... ist sie aber nicht ... sie kriecht immer noch im absoluten keller herum.
... die 600 entsprächen 30 Mrd Marktkapitalisierung. Ich freu mich schon mal auf die 3 Mrd MK bei 60$, falls wir nicht vorher schon aufgekauft wurden.
Noch ein netter Artikel:
"..When Sephora can't keep the product stocked on its shelves, that's when you know you have a hit on your hands. Biossance has five squalane-based products: 100 percent Squalane Oil ($58), Squalane + Peptide Eye Gel ($54), Squalane + Vitamin C Rose Oil ($72), Squalane + Probiotic Gel Moisturizer ($52), and Squalane + Antioxidant Cleansing Oil ($30)..."